Medtronic Wins Expanded Indication for SelectSecure(TM) MRI SureScan(TM) Pacing Lead for His Bundle Site Stimulation
July 12 2018 - 9:20AM
DUBLIN - July 12, 2018 -
Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug
Administration (FDA) labeling expansion for the Medtronic
SelectSecure(TM) MRI SureScan(TM) Model 3830 cardiac pacing lead to
include stimulation of the bundle of His. It is the only pacing
lead on the market approved for His-bundle pacing (HBP).
The steroid-eluting, bipolar SelectSecure SureScan
MRI model 3830 lead (lengths of 59, 69 and 74 cm) is attached to a
single or dual chamber pacemaker, and approved for pacing and
sensing in the atrium, right ventricle, or at the bundle of His as
an alternative to right ventricular pacing. Lead placement at or
near the bundle of His can be facilitated by the Medtronic C315HIS
delivery catheter. Permanent His bundle pacing is a physiologic
alternative to right ventricular pacing, harnessing the heart's
native His-Purkinje system.
"There is growing interest among some physicians
in His-bundle pacing as an alternative to right ventricular pacing,
and we are pleased to offer the SelectSecure MRI lead for those who
would like the option of this pacing approach for appropriate
patients," said Rob Kowal, M.D., Ph.D., vice president and chief
medical officer of the Cardiac Rhythm and Heart Failure division,
which is part of the Cardiac and Vascular Group at Medtronic.
In collaboration with leading clinicians,
researchers and scientists worldwide, Medtronic offers the broadest
range of innovative medical technology for the interventional and
surgical treatment of cardiovascular disease and cardiac
arrhythmias. Medtronic strives to offer products and services of
the highest quality that deliver clinical and economic value to
healthcare consumers and providers around the world.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 86,000 people worldwide, serving physicians,
hospitals and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Tracy McNulty
Public Relations
+1-763-526-2492
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024